The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of
malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered …

Most patients affected by malignant pleural mesothelioma (MPM) are candidates for
chemotherapy during the course of the disease, as single modality treatment or within the …

The role of second-line therapy in patients with malignant pleural mesothelioma (MPM)
progressing after first-line pemetrexed-based chemotherapy (PBC) is currently undefined …

Introduction Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is
increasing in frequency worldwide. Treatment options are limited, and response to …

Background This clinical practice guideline, based on a systematic review, was developed
to determine which chemotherapeutic agents (or combinations of agents) show the highest …

Cisplatin plus pemetrexed has been standard systemic therapy for malignant pleural
mesothelioma (MPM) since the landmark randomized trial reported in 2003. However, the …

Background In a randomized phase III trial, pemetrexed plus cisplatin was associated with
improved survival compared with cisplatin alone for patients with malignant pleural …

Introduction Treatment of malignant pleural mesothelioma (MPM) remains a clinical
challenge. The aim of this study was to identify selection factors for allocation of MPM …

Introduction Pemetrexed has established efficacy, and is the backbone for chemotherapy in
patients with malignant pleural mesothelioma (MPM). An International Expanded Access …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …